SCHEMBL25366993

SCHEMBL25366993

Cc1cccc(C2=CC(CO)N(C(=O)OC(C)(C)C)C2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.42
DPP4 P27487 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
GRM5 P41594 1/20 0.39
NPSR1 Q6W5P4 2/20 0.39
MAPT P10636 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
UCHL1 P09936 1/20 0.39
KAT7 O95251 1/20 0.38
KAT6A Q92794 2/20 0.38
KAT5 Q92993 2/20 0.38
LMNA P02545 1/20 0.37
CYP1A2 P05177 1/20 0.36
POLB P06746 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
NR1H2 P55055 8/20 0.35
NR1H3 Q13133 7/20 0.35
RXRA P19793 6/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25366989 1.00 GPR119 (0.42) GPR119DPP4MEN1KMT2AGRM5
SCHEMBL29035461 0.87 UCHL1 (0.46) GPR119MEN1KMT2AUCHL1NR1H2
SCHEMBL29035464 0.87 UCHL1 (0.46) GPR119MEN1KMT2AUCHL1NR1H2
SCHEMBL25362732 0.83 ALDH1A1 (0.38) MEN1KMT2AMAPTCYP3A4
SCHEMBL25362727 0.83 ALDH1A1 (0.38) MEN1KMT2AMAPTCYP3A4
SCHEMBL29880634 0.83 GPR119 (0.42) GPR119DPP4MEN1KMT2AGRM5
SCHEMBL23452587 0.83 GPR119 (0.42) GPR119DPP4MEN1KMT2AGRM5
SCHEMBL23452582 0.83 GPR119 (0.42) GPR119DPP4MEN1KMT2AGRM5
SCHEMBL25363576 0.82 DPP4 (0.41) GPR119DPP4MEN1KMT2AGRM5
SCHEMBL25363581 0.82 DPP4 (0.41) GPR119DPP4MEN1KMT2AGRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4216946-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Achillion Pharmaceuticals, Inc. (US) 2023-08-02 EP disclosed
CN-116437913-A Pharmaceutical compounds for treating complement-mediated disorders 艾其林医药公司 2023-07-14 CN disclosed